The Gujarat-based company, which manufactures pharmaceutical chemicals from its facility in Ankleshwar, has witnessed a dramatic reversal of fortunes. While net sales in Q4 FY26 stood at ₹71.77 crores—marginally up 0.80% year-on-year—the company slipped into deep operational losses with an operating profit (PBDIT excluding other income) of negative ₹1.24 crores, marking the worst quarterly performance since records began. This represents a catastrophic swing from the ₹0.12 crores operating profit recorded in Q4 FY25.
The stock's sharp decline on June 01, 2026 extended the company's year-to-date losses to 7.61%, though this still outperformed the Sensex's 12.33% decline over the same period. However, on a one-year basis, Samrat Pharmachem has underperformed dramatically, losing 47.49% compared to the Sensex's 8.27% decline—an alpha of negative 39.22 percentage points.
Financial Performance: A Quarter of Reckoning
The March 2026 quarter revealed severe operational distress across all key metrics. Net sales of ₹71.77 crores represented a modest 0.80% year-on-year increase but a sequential improvement of 13.15% from the December 2025 quarter's ₹63.43 crores. However, this top-line growth masked a complete collapse in profitability. The company's operating profit margin (excluding other income) turned deeply negative at -1.73%, compared to a positive 0.17% in Q4 FY25 and 6.55% in Q4 FY24.
The profit before tax plunged to negative ₹1.87 crores from negative ₹0.36 crores in the year-ago quarter. After accounting for a tax credit of ₹0.16 crores (resulting in an unusual negative tax rate of -8.56%), the company reported a net loss of ₹2.04 crores. This represents the company's worst quarterly performance in recent history, with the PAT margin collapsing to -2.84% from -0.56% a year earlier.
| Quarter | Net Sales (₹ Cr) | QoQ Growth | Operating Profit (₹ Cr) | Op. Margin % | Net Profit (₹ Cr) | PAT Margin % |
|---|---|---|---|---|---|---|
| Mar'26 | 71.77 | +13.15% | -1.24 | -1.73% | -2.04 | -2.84% |
| Dec'25 | 63.43 | -19.58% | -0.65 | -1.02% | -0.46 | -0.73% |
| Sep'25 | 78.87 | +4.26% | -0.36 | -0.46% | -0.59 | -0.75% |
| Jun'25 | 75.65 | +6.25% | 0.12 | 0.16% | -0.23 | -0.30% |
| Mar'25 | 71.20 | +11.84% | 0.12 | 0.17% | -0.40 | -0.56% |
| Dec'24 | 63.66 | -9.28% | 4.17 | 6.55% | 2.78 | 4.37% |
| Sep'24 | 70.17 | — | 3.36 | 4.79% | 2.66 | 3.79% |
The sequential quarterly trend reveals a disturbing pattern. After reporting healthy operating profits in the December 2024 and September 2024 quarters (₹4.17 crores and ₹3.36 crores respectively), the company has now posted four consecutive quarters of either marginal profits or outright losses. The June 2025 quarter marked the turning point, with operating profit collapsing to just ₹0.12 crores, followed by three consecutive quarters of operating losses.
Operational Breakdown: What Went Wrong?
The company's operational challenges stem from a complete erosion of gross profitability. While employee costs remained relatively stable at ₹0.69 crores in Q4 FY26 (compared to ₹0.66 crores in Q4 FY25), the company's inability to control other operating expenses relative to revenue growth has proven catastrophic. The gross profit margin turned deeply negative at -2.35% in the March 2026 quarter, compared to -0.29% a year earlier.
Interest costs, whilst modest at ₹0.14 crores in Q4 FY26, have remained relatively stable. However, the company recorded negative other income of ₹0.31 crores during the quarter, further pressuring profitability. This stands in stark contrast to the positive other income of ₹0.69 crores recorded in Q1 FY26 (June 2025 quarter), suggesting volatility in non-operating items.
Critical Red Flags
Profitability Collapse: Operating profit margin has deteriorated from 6.55% in Q4 FY24 to -1.73% in Q4 FY26, representing a swing of over 800 basis points. The company has posted four consecutive quarters of either marginal profits or losses, with Q4 FY26 marking the worst performance on record.
Quality of Earnings: The negative tax rate of -8.56% in Q4 FY26 and unusual tax patterns across recent quarters (ranging from -11.11% to 209.52%) raise serious questions about the sustainability and quality of reported earnings.
Looking at the full-year FY2025 performance provides additional context. For the fiscal year ended March 2025, Samrat Pharmachem reported net sales of ₹285.00 crores (up 1.40% from ₹281.00 crores in FY2024) and a net profit of ₹7.00 crores (up from ₹2.00 crores in FY2024). However, the operating profit margin for FY2025 stood at just 3.50%, significantly below the 7.40% achieved in FY2023, indicating structural margin pressure even before the recent quarterly deterioration.
Balance Sheet Strength: A Silver Lining
Despite the operational challenges, Samrat Pharmachem maintains a relatively healthy balance sheet. As of March 2025, the company had shareholder funds of ₹71.80 crores (comprising share capital of ₹3.09 crores and reserves of ₹68.71 crores) and carried zero long-term debt. This debt-free status is a significant positive, reflected in the company's average net debt to equity ratio of -0.12, indicating it is a net cash company.
The company's book value per share stands at ₹232.39, which at the current market price of ₹210.00 implies a price-to-book ratio of 1.09x—suggesting the stock trades marginally below its accounting value. Current assets of ₹103.36 crores as of March 2025 provide reasonable liquidity, though current liabilities of ₹49.58 crores (including trade payables of ₹38.70 crores) require careful monitoring.
Capital Efficiency Concerns
While the company's historical average Return on Equity (ROE) of 16.23% and Return on Capital Employed (ROCE) of 21.43% appear respectable, the latest ROE has plummeted to -2.38% as of March 2026, reflecting the recent loss-making quarters. The ROCE has similarly collapsed to 5.41%, indicating severely diminished capital efficiency. This represents a dramatic deterioration from the company's historical performance standards.
Cash Flow Analysis: Working Capital Strain
The company's cash flow statement for FY2025 reveals significant working capital challenges. Despite generating a profit before tax of ₹9.00 crores for the full year FY2025, changes in working capital consumed ₹19.00 crores, resulting in negative operating cash flow of ₹10.00 crores. This represents a sharp reversal from FY2024, when the company generated positive operating cash flow of ₹9.00 crores.
The working capital deterioration appears to be driven by increased current assets (rising from ₹102.57 crores in March 2024 to ₹103.36 crores in March 2025) and changes in trade payables. The company's closing cash position fell from ₹9.00 crores in March 2024 to zero in March 2025, indicating liquidity pressures despite the absence of debt.
Industry Context: Underperformance in a Recovering Sector
The pharmaceutical and biotechnology sector has delivered a one-year return of 9.50%, making Samrat Pharmachem's 47.49% decline over the same period particularly alarming. The company has underperformed its sector by 56.99 percentage points, suggesting company-specific challenges rather than broader industry headwinds.
The company's struggles stand in stark contrast to the sector's general resilience. Whilst larger pharmaceutical companies have benefited from robust domestic demand, export opportunities, and pricing power, Samrat Pharmachem's focus on pharmaceutical chemicals appears to have left it vulnerable to margin pressures, possibly from raw material cost inflation, pricing pressures from clients, or operational inefficiencies.
| Company | P/E Ratio | P/BV Ratio | ROE % | Debt/Equity | Dividend Yield |
|---|---|---|---|---|---|
| Samrat Pharmachem | NA (Loss Making) | 1.09x | 16.23% | -0.12x | 0.40% |
| Bharat Immunologicals | NA (Loss Making) | 0.96x | 0.00% | 0.83x | — |
| Bacil Pharma | 52.54x | 2.77x | 0.00% | -0.11x | — |
| Source Natural Foods | 20.89x | 2.75x | 13.14% | 0.22x | — |
| Amwill Healthcare | 6.10x | 0.89x | 44.17% | -0.16x | — |
| Sunil Healthcare | 22.77x | 0.96x | 4.97% | 0.84x | — |
Within its peer group of small-cap pharmaceutical companies, Samrat Pharmachem's historical average ROE of 16.23% compares favourably to most peers, though its current loss-making status eliminates any P/E-based valuation comparison. The company's price-to-book ratio of 1.09x is broadly in line with peers like Bharat Immunologicals (0.96x) and Sunil Healthcare (0.96x), but significantly below Source Natural Foods (2.75x) and Bacil Pharma (2.77x), reflecting market concerns about profitability sustainability.
Valuation Analysis: Fair Value in a Risky Context
At the current market price of ₹210.00, Samrat Pharmachem trades at a price-to-book value of 1.09x, marginally below its book value of ₹232.39 per share. The company's valuation grade stands at "FAIR" as of June 01, 2026, having been downgraded from "Attractive" in August 2025 and from "Very Attractive" earlier in the year. This valuation trajectory mirrors the deteriorating financial performance.
With the company currently loss-making, traditional earnings-based valuation metrics like P/E ratio are not applicable. The EV/EBITDA multiple of -68.49x and EV/EBIT of -46.59x (both negative due to operating losses) further underscore the valuation challenges. The EV/Sales ratio of 0.24x suggests the enterprise is valued at roughly one-quarter of annual revenues, which might appear attractive in normal circumstances but reflects significant profitability concerns.
| Metric | Current Value | Assessment |
|---|---|---|
| P/E Ratio (TTM) | NA (Loss Making) | Not Applicable |
| Price to Book Value | 1.09x | Below Book Value |
| Dividend Yield | 0.40% | Minimal Income |
| Overall Rating | 9/100 | Strong Sell |
The stock has declined 46.02% from its 52-week high of ₹389.00, though it remains 10.53% above its 52-week low of ₹190.00. The dividend yield of 0.40% (based on the latest dividend of ₹1.00 per share, ex-date September 18, 2025) provides minimal income support. With a dividend payout ratio of just 4.34% for FY2025, there is theoretically room for increased distributions, but the current loss-making status makes any dividend increase highly unlikely.
Shareholding Pattern: Stable Promoter Base, Volatile Institutions
The company's shareholding pattern reveals a stable promoter base holding 49.09% across the last five quarters through March 2026, with no change in promoter stake. The Mehta family dominates promoter holdings, with Lalit Damodar Mehta (13.97%), Rajesh Lalit Mehta (12.41%), and Premal Lalit Mehta (5.67%) being the largest individual shareholders. Critically, there is zero promoter pledging, which removes one potential risk factor.
| Category | Mar'26 | Dec'25 | Sep'25 | Jun'25 | QoQ Change |
|---|---|---|---|---|---|
| Promoter | 49.09% | 49.09% | 49.09% | 49.09% | 0.00% |
| FII | 0.00% | 3.24% | 3.24% | 0.00% | -3.24% |
| Mutual Funds | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other DII | 3.24% | 0.00% | 0.00% | 3.24% | +3.24% |
| Non-Institutional | 47.67% | 47.67% | 47.67% | 47.67% | 0.00% |
However, institutional participation tells a concerning story. Foreign Institutional Investors (FIIs) held 3.24% in the September and December 2025 quarters but completely exited by March 2026, reducing their stake to zero. This 3.24 percentage point reduction coincided with the company's worst quarterly performance, suggesting institutional investors recognised deteriorating fundamentals early.
Mutual fund participation remains at zero across all periods, whilst Other Domestic Institutional Investors (DIIs) have shown volatility, moving from 3.24% in June 2025 to zero in the subsequent two quarters, before returning to 3.24% in March 2026. The non-institutional shareholding of 47.67% has remained stable, representing retail and other non-institutional investors. The total institutional holding of just 3.24% reflects limited institutional confidence in the company's prospects.
Stock Performance: Severe Underperformance Across Timeframes
Samrat Pharmachem's stock performance has been dismal across virtually all timeframes. The one-day decline of 15.63% on June 01, 2026 significantly underperformed the Sensex's 0.08% decline, generating negative alpha of 15.55 percentage points. Over the past week, the stock has fallen 9.58% versus the Sensex's 2.32% decline, whilst the one-month performance shows a marginal 0.52% decline against the benchmark's 2.86% fall—one of the few periods of relative outperformance.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Day | -15.63% | -0.08% | -15.55% |
| 1 Week | -9.58% | -2.32% | -7.26% |
| 1 Month | -0.52% | -2.86% | +2.34% |
| 3 Months | +0.29% | -8.08% | +8.37% |
| 6 Months | -14.39% | -12.76% | -1.63% |
| YTD | -7.61% | -12.33% | +4.72% |
| 1 Year | -47.49% | -8.27% | -39.22% |
| 2 Years | -40.92% | +1.02% | -41.94% |
| 3 Years | -51.75% | +19.68% | -71.43% |
The longer-term picture is equally troubling. Over one year, the stock has lost 47.49% whilst the Sensex declined just 8.27%, resulting in negative alpha of 39.22 percentage points. The two-year return stands at -40.92% versus the Sensex's positive 1.02%, whilst the three-year return shows a devastating 51.75% loss against the benchmark's 19.68% gain. Only the 10-year return of 725.15% shows significant outperformance (versus Sensex's 179.69%), reflecting the company's much lower base a decade ago.
The stock's beta of 1.50 indicates it is 50% more volatile than the market, classified as a "High Beta" stock. With a one-year volatility of 42.70% compared to the Sensex's 13.06%, the stock exhibits more than three times the market's volatility. The risk-adjusted return of -1.11 for the one-year period (versus -0.63 for the Sensex) confirms that investors have been penalised with both high volatility and negative returns—the worst possible combination.
Technical Analysis: Deeply Bearish Signals
The technical picture for Samrat Pharmachem is overwhelmingly negative. The current trend is classified as "MILDLY BEARISH" as of May 21, 2026 at ₹222, having previously been in a "Bearish" trend. The stock trades below all major moving averages: the 5-day MA (₹232.83), 20-day MA (₹217.72), 50-day MA (₹213.22), 100-day MA (₹214.86), and critically, the 200-day MA (₹253.13).
Technical indicators paint a mixed but predominantly negative picture. The MACD shows "Mildly Bullish" on the weekly chart but "Bearish" on the monthly timeframe. Bollinger Bands indicate "Bullish" on the weekly but "Mildly Bearish" on the monthly. Moving averages are "Mildly Bearish" on the weekly chart. The KST oscillator shows "Mildly Bullish" weekly but "Bearish" monthly, whilst Dow Theory indicates "Mildly Bullish" on both timeframes.
Immediate support rests at the 52-week low of ₹190.00, just 9.52% below current levels, suggesting limited downside cushion. Immediate resistance appears at the 20-day moving average of ₹217.72, followed by the 100-day MA at ₹214.86. Major resistance sits at the 200-day MA of ₹253.13, representing 20.54% upside, whilst the 52-week high of ₹389.00 stands as a distant target 85.24% above current levels.
Investment Thesis: Fundamental Deterioration Outweighs Balance Sheet Strength
Samrat Pharmachem's investment case has deteriorated significantly. The company's proprietary Mojo Score stands at just 9 out of 100, firmly in "STRONG SELL" territory (score range 0-30). This represents a dramatic fall from grace for a company that historically generated respectable returns on capital and maintained a debt-free balance sheet.
The quality assessment has been downgraded to "BELOW AVERAGE" from "Average" prior to August 2025, reflecting the sustained operational deterioration. The financial trend is classified as "NEGATIVE" as of March 2026, with key negative factors including PAT falling 385.70% versus the previous four-quarter average, operating profit margin at its lowest level (-1.73%), and multiple metrics hitting record lows.
Key Strengths & Risk Factors
KEY STRENGTHS
- Debt-free balance sheet with zero long-term borrowings provides financial flexibility
- Net cash position (debt-to-equity of -0.12) eliminates solvency concerns
- Historical average ROE of 16.23% and ROCE of 21.43% demonstrate past capital efficiency
- Stable promoter holding of 49.09% with zero pledging shows commitment
- Book value of ₹232.39 per share provides downside cushion at current price of ₹210
- Five-year sales CAGR of 12.30% indicates long-term growth capability
- Low institutional holding of 3.24% leaves room for discovery if fundamentals improve
KEY CONCERNS
- Four consecutive quarters of operating losses with Q4 FY26 the worst on record
- Operating margin collapsed from 6.55% in Q4 FY24 to -1.73% in Q4 FY26
- Latest ROE plunged to -2.38% and ROCE to 5.41%, indicating severe capital efficiency deterioration
- Negative operating cash flow of ₹10.00 crores in FY2025 despite reported profit
- Complete FII exit in Q4 FY26 signals institutional loss of confidence
- Stock underperformed sector by 56.99 percentage points over one year
- High volatility (42.70%) with negative returns creates unfavourable risk-reward
- Unusual tax patterns and negative tax rates raise earnings quality concerns
Outlook: Critical Monitoring Points
POSITIVE CATALYSTS
- Return to operating profitability in Q1 FY27 would signal turnaround
- Operating margin recovery above 3-4% would restore investor confidence
- Positive operating cash flow generation indicating working capital improvement
- Institutional investor re-entry, particularly FII participation
- Management commentary on specific cost reduction or efficiency initiatives
RED FLAGS TO WATCH
- Fifth consecutive quarter of operating losses would confirm structural issues
- Further deterioration in operating margins below -2%
- Continued negative operating cash flow in FY2026
- Any promoter stake reduction or pledge of shares
- Stock breaking below 52-week low of ₹190 would signal capitulation
The immediate outlook for Samrat Pharmachem remains challenging. The company must demonstrate a clear path back to profitability in the coming quarters to prevent further value erosion. Investors should closely monitor the Q1 FY27 results for any signs of operational stabilisation or continued deterioration. The absence of debt provides breathing room, but without revenue growth and margin recovery, the company faces the prospect of sustained losses that will eventually erode its equity base.
The Verdict: Avoid Until Turnaround Evidence Emerges
Score: 9/100
For Fresh Investors: Avoid initiating positions. The company's operational collapse, four consecutive quarters of losses, and institutional investor exodus present unacceptable risk. Whilst the debt-free balance sheet provides some cushion, the deteriorating fundamentals and negative financial trend warrant staying away until clear evidence of a sustainable turnaround emerges.
For Existing Holders: Consider exiting on any relief rallies. The 15.63% single-day decline on June 01, 2026 following Q4 results reflects market recognition of severe fundamental deterioration. With the stock trading below book value and operating margins deeply negative, the risk-reward ratio remains unfavourable. Only investors with very high risk tolerance and a long-term horizon should consider holding, and even then, strict monitoring of quarterly results is essential.
Fair Value Estimate: ₹175-190 (17-10% downside from current levels) based on 0.75-0.82x price-to-book, reflecting below-average quality and negative earnings trajectory. Any sustained return to profitability could support a re-rating towards book value of ₹232.
Note— ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. Investments in equity securities involve substantial risk and may result in partial or total loss of capital.
